FLT1 and cancer: Moreover, VEGF is a clinically validated target for antiangiogeneic therapy for cancer, and agents that block PlGF or the tyrosine kinase activity of their cognate receptor VEGFR1 are currently approved for cancer treatment or in clinical trials (sunitinib, sorafenib, cediranib, axitinib, pazopanib, BIBF1120, etc.)[1], [2], [3].